Physician profile
Soon John Park
NPI 1891716544
$1,499.23
in general payments reported to CMS, 2019-2025
12 companies · $233 in 2025
The $233 reported for 2025 was less than what a typical Thoracic Surgery (Cardiothoracic Vascular Surgery) provider received nationally (typical 2025 total: $796).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $471 · 2020: $13.30 · 2021: $143 · 2022: $73.17 · 2023: $210 · 2024: $356 · 2025: $233.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $799.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $799.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $420.08 | 2022-2025 | Penditure, Avalus, Cardioblate |
| Abbott Laboratories | $413.05 | 2019-2021 | |
| Abiomed | $208.66 | 2022-2025 | Impella |
| Getinge USA Sales, LLC | $130.42 | 2019 | |
| Atricure, INC. | $87.78 | 2023-2025 | Atriclip Laa Exclusion System, Epi-Sense Guided Coagulation System With Visitrax |
| Edwards Lifesciences Corporation | $74.50 | 2021-2025 | Mitris Resilia Mitral Valve, Inspiris Resilia Aortic Valve |
| Zimmer Biomet Holdings, INC. | $50.19 | 2023 | |
| Becton, Dickinson and Company | $32.40 | 2025 | Arista |
| Lemaitre Vascular, INC. | $25.90 | 2024 | Pruitt F3 Carotid Shunt |
| Janssen Pharmaceuticals, INC | $23.78 | 2021 | |
| Davol INC. | $19.17 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $13.30 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Soon Park listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.